Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
73
CLYM Quote, Financials, Valuation and Earnings
Last price:
$5.46
Seasonality move
:
38.16%
Day range:
$5.37 - $5.60
52-week range:
$1.05 - $6.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.12x
Volume:
347.8K
Avg. volume:
675K
1-year change:
259.48%
Market cap:
$375M
Revenue:
--
EPS (TTM):
-$0.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CLYM
Climb Bio, Inc.
|
-- | -$0.21 | -- | -31.82% | $11.43 |
|
FBIO
Fortress Biotech, Inc.
|
$26.2M | -$0.31 | 73.08% | -72.5% | $10.75 |
|
LYEL
Lyell Immunopharma, Inc.
|
-- | -$2.30 | -100% | -1177.78% | $29.67 |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
-- | -$0.07 | -- | -75% | $3.25 |
|
PEPG
PepGen Inc.
|
-- | -$0.37 | -- | -46.13% | $10.17 |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$3.2B | $5.15 | 11.14% | 76.99% | $530.07 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CLYM
Climb Bio, Inc.
|
$5.50 | $11.43 | $375M | -- | $0.00 | 0% | -- |
|
FBIO
Fortress Biotech, Inc.
|
$3.45 | $10.75 | $107.1M | -- | $0.00 | 0% | 1.62x |
|
LYEL
Lyell Immunopharma, Inc.
|
$24.39 | $29.67 | $361.2M | -- | $0.00 | 0% | 88,443.14x |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
$3.30 | $3.25 | $131.3M | 3.29x | $0.25 | 7.58% | 68.69x |
|
PEPG
PepGen Inc.
|
$6.54 | $10.17 | $449.6M | -- | $0.00 | 0% | -- |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$470.31 | $530.07 | $119.5B | 30.67x | $0.00 | 0% | 10.05x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CLYM
Climb Bio, Inc.
|
0.33% | 0.143 | 0.42% | 17.56x |
|
FBIO
Fortress Biotech, Inc.
|
55.01% | 0.810 | 55.12% | 1.93x |
|
LYEL
Lyell Immunopharma, Inc.
|
13.89% | 1.431 | 22.07% | 10.03x |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
0.42% | -0.079 | 0.8% | 22.01x |
|
PEPG
PepGen Inc.
|
9.66% | 4.797 | 5.49% | 12.95x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
9.84% | -0.890 | 1.77% | 2.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CLYM
Climb Bio, Inc.
|
-$29K | -$14.9M | -25.66% | -25.72% | -- | -$12.2M |
|
FBIO
Fortress Biotech, Inc.
|
$10.7M | -$6.8M | -56.09% | -223.06% | -38.63% | -$6.1M |
|
LYEL
Lyell Immunopharma, Inc.
|
-$2.6M | -$38.8M | -75.65% | -86.7% | -258960% | -$28.6M |
|
ORMP
Oramed Pharmaceuticals, Inc.
|
-$31K | -$2.4M | 27.4% | 27.49% | -225% | -$2M |
|
PEPG
PepGen Inc.
|
-$339K | -$18.7M | -69.46% | -80.35% | -- | -$19.4M |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$2.8B | $1.3B | 20.84% | 22.97% | 40.3% | $348.6M |
Climb Bio, Inc. vs. Competitors
-
Which has Higher Returns CLYM or FBIO?
Fortress Biotech, Inc. has a net margin of -- compared to Climb Bio, Inc.'s net margin of 50.07%. Climb Bio, Inc.'s return on equity of -25.72% beat Fortress Biotech, Inc.'s return on equity of -223.06%.
Company Gross Margin Earnings Per Share Invested Capital CLYMClimb Bio, Inc.-- -$0.19 $177.6M FBIOFortress Biotech, Inc.60.8% $0.11 $133.5M -
What do Analysts Say About CLYM or FBIO?
Climb Bio, Inc. has a consensus price target of $11.43, signalling upside risk potential of 107.79%. On the other hand Fortress Biotech, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 211.59%. Given that Fortress Biotech, Inc. has higher upside potential than Climb Bio, Inc., analysts believe Fortress Biotech, Inc. is more attractive than Climb Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLYMClimb Bio, Inc.7 0 0 FBIOFortress Biotech, Inc.2 0 0 -
Is CLYM or FBIO More Risky?
Climb Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech, Inc. has a beta of 1.433, suggesting its more volatile than the S&P 500 by 43.28%.
-
Which is a Better Dividend Stock CLYM or FBIO?
Climb Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio, Inc. pays -- of its earnings as a dividend. Fortress Biotech, Inc. pays out 3.9% of its earnings as a dividend. Fortress Biotech, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CLYM or FBIO?
Climb Bio, Inc. quarterly revenues are --, which are smaller than Fortress Biotech, Inc. quarterly revenues of $17.6M. Climb Bio, Inc.'s net income of -$12.9M is lower than Fortress Biotech, Inc.'s net income of $8.8M. Notably, Climb Bio, Inc.'s price-to-earnings ratio is -- while Fortress Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio, Inc. is -- versus 1.62x for Fortress Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLYMClimb Bio, Inc.-- -- -- -$12.9M FBIOFortress Biotech, Inc.1.62x -- $17.6M $8.8M
-
Which has Higher Returns CLYM or LYEL?
Lyell Immunopharma, Inc. has a net margin of -- compared to Climb Bio, Inc.'s net margin of -258973.33%. Climb Bio, Inc.'s return on equity of -25.72% beat Lyell Immunopharma, Inc.'s return on equity of -86.7%.
Company Gross Margin Earnings Per Share Invested Capital CLYMClimb Bio, Inc.-- -$0.19 $177.6M LYELLyell Immunopharma, Inc.-17006.67% -$2.13 $382.2M -
What do Analysts Say About CLYM or LYEL?
Climb Bio, Inc. has a consensus price target of $11.43, signalling upside risk potential of 107.79%. On the other hand Lyell Immunopharma, Inc. has an analysts' consensus of $29.67 which suggests that it could grow by 21.64%. Given that Climb Bio, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Climb Bio, Inc. is more attractive than Lyell Immunopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLYMClimb Bio, Inc.7 0 0 LYELLyell Immunopharma, Inc.2 0 0 -
Is CLYM or LYEL More Risky?
Climb Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lyell Immunopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CLYM or LYEL?
Climb Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lyell Immunopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio, Inc. pays -- of its earnings as a dividend. Lyell Immunopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLYM or LYEL?
Climb Bio, Inc. quarterly revenues are --, which are smaller than Lyell Immunopharma, Inc. quarterly revenues of $15K. Climb Bio, Inc.'s net income of -$12.9M is higher than Lyell Immunopharma, Inc.'s net income of -$38.8M. Notably, Climb Bio, Inc.'s price-to-earnings ratio is -- while Lyell Immunopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio, Inc. is -- versus 88,443.14x for Lyell Immunopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLYMClimb Bio, Inc.-- -- -- -$12.9M LYELLyell Immunopharma, Inc.88,443.14x -- $15K -$38.8M
-
Which has Higher Returns CLYM or ORMP?
Oramed Pharmaceuticals, Inc. has a net margin of -- compared to Climb Bio, Inc.'s net margin of -382.1%. Climb Bio, Inc.'s return on equity of -25.72% beat Oramed Pharmaceuticals, Inc.'s return on equity of 27.49%.
Company Gross Margin Earnings Per Share Invested Capital CLYMClimb Bio, Inc.-- -$0.19 $177.6M ORMPOramed Pharmaceuticals, Inc.0.65% $1.13 $203.2M -
What do Analysts Say About CLYM or ORMP?
Climb Bio, Inc. has a consensus price target of $11.43, signalling upside risk potential of 107.79%. On the other hand Oramed Pharmaceuticals, Inc. has an analysts' consensus of $3.25 which suggests that it could fall by -1.52%. Given that Climb Bio, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Climb Bio, Inc. is more attractive than Oramed Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLYMClimb Bio, Inc.7 0 0 ORMPOramed Pharmaceuticals, Inc.0 0 0 -
Is CLYM or ORMP More Risky?
Climb Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oramed Pharmaceuticals, Inc. has a beta of 1.342, suggesting its more volatile than the S&P 500 by 34.249%.
-
Which is a Better Dividend Stock CLYM or ORMP?
Climb Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals, Inc. offers a yield of 7.58% to investors and pays a quarterly dividend of $0.25 per share. Climb Bio, Inc. pays -- of its earnings as a dividend. Oramed Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLYM or ORMP?
Climb Bio, Inc. quarterly revenues are --, which are smaller than Oramed Pharmaceuticals, Inc. quarterly revenues of --. Climb Bio, Inc.'s net income of -$12.9M is lower than Oramed Pharmaceuticals, Inc.'s net income of $48.4M. Notably, Climb Bio, Inc.'s price-to-earnings ratio is -- while Oramed Pharmaceuticals, Inc.'s PE ratio is 3.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio, Inc. is -- versus 68.69x for Oramed Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLYMClimb Bio, Inc.-- -- -- -$12.9M ORMPOramed Pharmaceuticals, Inc.68.69x 3.29x -- $48.4M
-
Which has Higher Returns CLYM or PEPG?
PepGen Inc. has a net margin of -- compared to Climb Bio, Inc.'s net margin of --. Climb Bio, Inc.'s return on equity of -25.72% beat PepGen Inc.'s return on equity of -80.35%.
Company Gross Margin Earnings Per Share Invested Capital CLYMClimb Bio, Inc.-- -$0.19 $177.6M PEPGPepGen Inc.-- -$0.52 $180.6M -
What do Analysts Say About CLYM or PEPG?
Climb Bio, Inc. has a consensus price target of $11.43, signalling upside risk potential of 107.79%. On the other hand PepGen Inc. has an analysts' consensus of $10.17 which suggests that it could grow by 55.45%. Given that Climb Bio, Inc. has higher upside potential than PepGen Inc., analysts believe Climb Bio, Inc. is more attractive than PepGen Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLYMClimb Bio, Inc.7 0 0 PEPGPepGen Inc.5 0 0 -
Is CLYM or PEPG More Risky?
Climb Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PepGen Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CLYM or PEPG?
Climb Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PepGen Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio, Inc. pays -- of its earnings as a dividend. PepGen Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLYM or PEPG?
Climb Bio, Inc. quarterly revenues are --, which are smaller than PepGen Inc. quarterly revenues of --. Climb Bio, Inc.'s net income of -$12.9M is higher than PepGen Inc.'s net income of -$18M. Notably, Climb Bio, Inc.'s price-to-earnings ratio is -- while PepGen Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio, Inc. is -- versus -- for PepGen Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLYMClimb Bio, Inc.-- -- -- -$12.9M PEPGPepGen Inc.-- -- -- -$18M
-
Which has Higher Returns CLYM or VRTX?
Vertex Pharmaceuticals, Inc. has a net margin of -- compared to Climb Bio, Inc.'s net margin of 36.91%. Climb Bio, Inc.'s return on equity of -25.72% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.
Company Gross Margin Earnings Per Share Invested Capital CLYMClimb Bio, Inc.-- -$0.19 $177.6M VRTXVertex Pharmaceuticals, Inc.85.56% $4.65 $20.7B -
What do Analysts Say About CLYM or VRTX?
Climb Bio, Inc. has a consensus price target of $11.43, signalling upside risk potential of 107.79%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $530.07 which suggests that it could grow by 12.71%. Given that Climb Bio, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Climb Bio, Inc. is more attractive than Vertex Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLYMClimb Bio, Inc.7 0 0 VRTXVertex Pharmaceuticals, Inc.21 5 1 -
Is CLYM or VRTX More Risky?
Climb Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.
-
Which is a Better Dividend Stock CLYM or VRTX?
Climb Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Climb Bio, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLYM or VRTX?
Climb Bio, Inc. quarterly revenues are --, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Climb Bio, Inc.'s net income of -$12.9M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Climb Bio, Inc.'s price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 30.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Climb Bio, Inc. is -- versus 10.05x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLYMClimb Bio, Inc.-- -- -- -$12.9M VRTXVertex Pharmaceuticals, Inc.10.05x 30.67x $3.2B $1.2B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 1.25% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 3.96% over the past day.
Sell
37
ACLS alert for Feb 19
Axcelis Technologies, Inc. [ACLS] is down 1.4% over the past day.
